众生药业2025年第三季度净利润2.51亿元同比增长68.40%

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. reported a slight decline in revenue for the first three quarters of 2025, indicating challenges in the market while emphasizing its strategic focus on innovation and cost control [1] Financial Performance - The company achieved an operating income of 1.889 billion yuan, representing a year-on-year decrease of 1.01% [1] Strategic Initiatives - Zhongsheng Pharmaceutical employs a three-pronged strategy of research, production, and sales to optimize operations and implement cost-cutting measures, creating a closed loop of breakthroughs in research, guaranteed production, and increased sales [1] - The company is the only domestic entity with innovative drugs for both COVID-19 and influenza, actively advancing the commercialization of Le Rui Ling® and An Rui Wei® to enhance the treatment of these diseases [1] Research and Development - The company focuses on independent research and development, integrating internal and external resources to proactively conduct innovative drug research [1] - Zhongsheng Pharmaceutical leverages its advantages in small molecule and peptide drug research technology platforms, targeting differentiated early research pipelines in respiratory and metabolic diseases [1]